Compare iShares MSCI Japan ETF (EWJ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Japan ETF trades at $94.78 (market cap $23.55B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: iShares MSCI Japan ETF is far larger — about 6.3× Tango Therapeutics Inc.'s market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWJ | TNGX | |
|---|---|---|
Market Cap | $23.55B | $3.75B |
Volume | 1,896,806 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $32.90 |
52-Week Low | $79.49 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.32 with no significant daily movement. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. The ETF benefits from Japan's economic developments including recent Bank of Japan rate hikes and fiscal stimulus measures. Support and resistance levels cluster tightly around the current price, indicating potential for breakout movement.
The outlook for EWJ appears cautiously optimistic as Japan navigates monetary policy normalization while maintaining growth stimulus. Investment opportunities include exposure to Japan's AI and semiconductor sectors, though risks persist from yen volatility, rising bond yields, and global macroeconomic pressures. The ETF's performance relative to the S&P 500 in 2026 suggests international diversification benefits.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
